GRAFNOS
| Active Ingredient | Tacrolimus |
| Strength | 0.25 mg / 0.5 mg / 1 mg / 2 mg |
| Dosage Form | Capsule |
| Route of Administration | Oral |
| Pack Details | 1 x 10 Capsules |
Indication:
1. Prophylaxis of organ rejection in patients receiving Allogeneic Liver, Kidney or Heart
Transplants
2. Use concomitantly with Mycophenolate Mofetil and Corticosteroids
CONVOTOS
| Active Ingredient | Mycophenolate Mofetil |
| Strength | 500 mg |
| Dosage Form | Tablet |
| Route of Administration | Oral |
| Pack Details | 1 x 10 Tablets |
Indication:
1. Prophylaxis of organ rejection in patients receiving Allogeneic Liver, Kidney or Heart
transplants
2. Use concomitantly with Tacrolimus and Corticosteroids
CONVOTOS-S
| Active Ingredient | Mycophenolate Sodium |
| Strength | 180 mg / 360 mg |
| Dosage Form | Tablet (Delayed-Release) |
| Route of Administration | Oral |
| Pack Details | 1 x 10 Tablets |
Indication:
1. Prophylaxis of organ rejection in patients receiving Allogeneic Liver, Kidney or Heart
Transplants
2. Use concomitantly with Tacrolimus and Corticosteroids
3. Mycophenolate sodium provides an alternative to Mycophenolate Mofetil in Transplant
Patients to avoid GI complications
VYLSTER
| Active Ingredient | Valganciclovir Hydrochloride |
| Strength | 450 mg |
| Dosage Form | Tablet |
| Route of Administration | Oral |
| Pack Details | 1 x 2 Tablets |
Indication:
1. Drug of Choice for both Prophylaxis & treatment of CMV disease in Kidney, Heart, or
Kidney-Pancreas Transplant patients at high risk
2. Treatment of CMV retinitis in patients with Acquired Immunodeficiency Syndrome (AIDS)
3. Prevention of CMV disease in Kidney or Heart transplant pediatric patients at high risk
CYKLONOS
| Active Ingredient | Cyclosporine |
| Strength | 25 mg / 50 mg / 100 mg |
| Dosage Form | Capsule |
| Route of Administration | Oral |
| Pack Details | 1 x 6 Capsules (Blister Pack) |
Indication:
1. Solid Organ Transplant
2. Bone Marrow Transplant
3. Aplastic Anemia , Psoriasis, Rheumatoid Arthritis and Nephrotic Syndrome